Sygnature Discovery signs drug discovery deal with Sitryx Therapeutics

| By | Drug Development, Pharmaceutical Deal, R&D
0
102

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, announced a multi-target, integrated drug discovery collaboration with Sitryx Therapeutics, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

The energetic status of cells has been shown to be pivotal in controlling the behaviour of disease associated cells in immuno-oncology and immuno-inflammation. Correcting immune cell function and/or inhibiting tumour cell growth through targeting metabolic pathways has the potential to deliver new complementary and highly-differentiated approaches to treat a wide range of severe diseases.

Sitryx’s proprietary science is led by a highly-experienced management team, supported by GlaxoSmithKline’s drug discovery experience and world-class academic founders, in addition to Sygnature’s significant expertise in immuno-oncology and immunology drug discovery. Sitryx Therapeutics was founded by six world-leading researchers in the field of immunology and immuno-regulation, including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak.

Dr Simon Hirst, CEO and Founder of Sygnature, commented:

“We are pleased to have been selected by Sitryx to support their ground-breaking research efforts to develop disease-modifying therapeutics across multiple biological targets in immuno-oncology and immuno-inflammation. Our considerable in-house knowledge of immuno-oncology and immunology discovery will enable us to efficiently navigate these complex areas of biology to support the identification and optimisation of novel and selective small molecules while developing a deep understanding of their mode-of-action.”

Dr Neil Weir, CEO of Sitryx, said:

“Sygnature Discovery has an established reputation as a provider of premium integrated drug discovery and pre-clinical services and the Sitryx team has an extensive track record of success in the discovery and development of novel drugs. We will combine our considerable know-how and expertise to deliver new, highly-effective disease-modifying therapeutics in immuno-oncology and immuno-inflammation.”

Sygnature Discovery (Nottingham, UK) is a leading independent integrated drug discovery and pre-clinical services company. The company operates fully-enabled research facilities in Nottingham and Alderley Park (UK) housing over 200 research scientists (80% with PhDs). Since 2011, the company delivered 14 drug candidates to its clients which have subsequently entered the clinic (Phases I and II). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade.

Sitryx (Oxford, UK) is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The company, founded with seed funding from SV Health investors, has raised a total of $30 million in its Series A financing round from a syndicate of specialist international healthcare investors co-led by SV Health Investors and Sofinnova Partners, and also including Longwood Fund and the global healthcare company, GSK.

SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.